Outlook Therapeutics (NASDAQ:OTLK - Get Free Report) is anticipated to announce its Q2 2025 earnings results before the market opens on Wednesday, May 21st. Analysts expect the company to announce earnings of ($0.55) per share and revenue of $0.70 million for the quarter.
Outlook Therapeutics (NASDAQ:OTLK - Get Free Report) last posted its quarterly earnings data on Friday, February 14th. The company reported ($0.89) earnings per share for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.04). On average, analysts expect Outlook Therapeutics to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Outlook Therapeutics Stock Up 27.7%
OTLK stock opened at $2.03 on Wednesday. Outlook Therapeutics has a twelve month low of $0.87 and a twelve month high of $9.25. The stock has a market capitalization of $64.99 million, a price-to-earnings ratio of -0.27 and a beta of 0.39. The firm's fifty day simple moving average is $1.42 and its two-hundred day simple moving average is $2.27.
Analyst Upgrades and Downgrades
Several research analysts have issued reports on the stock. Ascendiant Capital Markets dropped their target price on shares of Outlook Therapeutics from $33.00 to $24.00 and set a "buy" rating on the stock in a report on Monday, February 24th. HC Wainwright cut their price objective on shares of Outlook Therapeutics from $30.00 to $3.00 and set a "buy" rating on the stock in a report on Tuesday, February 18th. Chardan Capital restated a "neutral" rating and set a $3.00 price objective on shares of Outlook Therapeutics in a report on Tuesday, February 18th. Finally, Guggenheim reiterated a "buy" rating and issued a $12.00 price target on shares of Outlook Therapeutics in a report on Friday, January 17th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $10.20.
Get Our Latest Research Report on OTLK
Outlook Therapeutics Company Profile
(
Get Free Report)
Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Outlook Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Outlook Therapeutics wasn't on the list.
While Outlook Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
